BioSpace News Archive

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, announced the presentation of preclinical data on BDTX-189 and BDTX-1535 at the American Association for Cancer Research Annual Meeting, taking place April 9-14, 2021.

Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202

Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, presented new findings on a range of investigational agents from the company’s pipeline at the American Association for Cancer Research Virtual Annual Meeting I, taking place April 10-15, 2021.

Evaluable participants (n=20) are heavily pretreated (median of 3 prior lines of treatment); an increase in progression-free survival is a desired outcome

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors.

Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster “Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer patients” at the 112th Annual Meeting of the American Association for Cancer Research on April 10, 2021, from 8:30 AM - 11:59 PM Eastern Daylight Time.

Blueprint Medicines Corporation announced data from multiple poster presentations highlighting the breadth of the company’s precision therapy pipeline at the virtual American Association for Cancer Research Annual Meeting 2021.

Preclinical data presented at the 2021 AACR Annual Virtual Meeting supports advancement of parallel lead programs in ROS1-positive and ALK-positive NSCLC

Results further support the investigation of monotherapy seribantumab for the treatment of solid tumors uniquely driven by an NRG1 fusion in the ongoing Phase 2 CRESTONE study